Chiara Bella
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chiara Bella has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Asifa Akhtar
Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
2 shared publications Cecilia Pessoa Rodrigues
Department of Chromatin Regulation, Max Planck Institute of Immunobiology and Epigenetics
2 shared publications- Maria Shvedunova
Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
2 shared publications - Meike Wiese
Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
2 shared publications Thomas Stehle
Department of Chromatin Regulation, Max Planck Institute of Immunobiology and Epigenetics
2 shared publications- Alejandro Villarreal
Instituto de Biología Celular y Neurociencia “Prof. E. De Robertis” UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Argentina
1 shared publication
Latest Publications
- Open Access
- 3 October 2025
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 8 (12) , e202503238
KANSL3 directs transcriptional programs essential for hepatic metabolism and differentiation
Liver disease is a leading cause of mortality worldwide. Emerging evidence highlights the significant role of epigenetic regulation in sustaining liver homeostasis, providing new therapeutic strategies for liver disease. Hepatocyte-specific deletion of the epigenetic regulator KANSL3, a key component of the NSL complex, results in early-onset liver disease marked by biliary hyperplasia and hepatic fibrosis. KANSL3 is essential for regulating hepatocyte transcriptional networks important for hepatic steroid and lipid metabolism through histone acetylation. Moreover, single-cell RNA sequencing demonstrated that the loss of KANSL3 disrupts the differentiation of hepatocytes in vivo. The transcriptional programs necessary for hepatocyte differentiation of ductal and fetal liver organoids were severely compromised in the absence of KANSL3. These findings collectively demonstrate a crucial role of the epigenetic regulator KANSL3 in hepatocyte differentiation in liver development and disease.
- 3 October 2025
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 8 (12) , e202503238
Open AccessKANSL3 directs transcriptional programs essential for hepatic metabolism and differentiation
Liver disease is a leading cause of mortality worldwide. Emerging evidence highlights the significant role of epigenetic regulation in sustaining liver homeostasis, providing new therapeutic strategies for liver disease. Hepatocyte-specific deletion of the epigenetic regulator KANSL3, a key component of the NSL complex, results in early-onset liver disease marked by biliary hyperplasia and hepatic fibrosis. KANSL3 is essential for regulating hepatocyte transcriptional networks important for hepatic steroid and lipid metabolism through histone acetylation. Moreover, single-cell RNA sequencing demonstrated that the loss of KANSL3 disrupts the differentiation of hepatocytes in vivo. The transcriptional programs necessary for hepatocyte differentiation of ductal and fetal liver organoids were severely compromised in the absence of KANSL3. These findings collectively demonstrate a crucial role of the epigenetic regulator KANSL3 in hepatocyte differentiation in liver development and disease.
- Open Access
- 29 November 2023
- Published by Springer Nature in Nature
- Vol. 624 (7990) , 173-181
MSL2 ensures biallelic gene expression in mammals
In diploid organisms, biallelic gene expression enables the production of adequate levels of mRNA1,2. This is essential for haploinsufficient genes, which require biallelic expression for optimal function to prevent the onset of developmental disorders1,3. Whether and how a biallelic or monoallelic state is determined in a cell-type-specific manner at individual loci remains unclear. MSL2 is known for dosage compensation of the male X chromosome in flies. Here we identify a role of MSL2 in regulating allelic expression in mammals. Allele-specific bulk and single-cell analyses in mouse neural progenitor cells revealed that, in addition to the targets showing biallelic downregulation, a class of genes transitions from biallelic to monoallelic expression after MSL2 loss. Many of these genes are haploinsufficient. In the absence of MSL2, one allele remains active, retaining active histone modifications and transcription factor binding, whereas the other allele is silenced, exhibiting loss of promoter–enhancer contacts and the acquisition of DNA methylation. Msl2-knockout mice show perinatal lethality and heterogeneous phenotypes during embryonic development, supporting a role for MSL2 in regulating gene dosage. The role of MSL2 in preserving biallelic expression of specific dosage-sensitive genes sets the stage for further investigation of other factors that are involved in allelic dosage compensation in mammalian cells, with considerable implications for human disease.
- 29 November 2023
- Published by Springer Nature in Nature
- Vol. 624 (7990) , 173-181
Open AccessMSL2 ensures biallelic gene expression in mammals
In diploid organisms, biallelic gene expression enables the production of adequate levels of mRNA1,2. This is essential for haploinsufficient genes, which require biallelic expression for optimal function to prevent the onset of developmental disorders1,3. Whether and how a biallelic or monoallelic state is determined in a cell-type-specific manner at individual loci remains unclear. MSL2 is known for dosage compensation of the male X chromosome in flies. Here we identify a role of MSL2 in regulating allelic expression in mammals. Allele-specific bulk and single-cell analyses in mouse neural progenitor cells revealed that, in addition to the targets showing biallelic downregulation, a class of genes transitions from biallelic to monoallelic expression after MSL2 loss. Many of these genes are haploinsufficient. In the absence of MSL2, one allele remains active, retaining active histone modifications and transcription factor binding, whereas the other allele is silenced, exhibiting loss of promoter–enhancer contacts and the acquisition of DNA methylation. Msl2-knockout mice show perinatal lethality and heterogeneous phenotypes during embryonic development, supporting a role for MSL2 in regulating gene dosage. The role of MSL2 in preserving biallelic expression of specific dosage-sensitive genes sets the stage for further investigation of other factors that are involved in allelic dosage compensation in mammalian cells, with considerable implications for human disease.
- Open Access
- 4 January 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (2)
Multimodal epigenetic changes and altered NEUROD1 chromatin binding in the mouse hippocampus underlie FOXG1 syndrome
Forkhead box G1 (FOXG1) has important functions in neuronal differentiation and balances excitatory/inhibitory network activity. Thus far, molecular processes underlying FOXG1 function are largely unexplored. Here, we present a multiomics data set exploring how FOXG1 impacts neuronal maturation at the chromatin level in the mouse hippocampus. At a genome-wide level, FOXG1 i) both represses and activates transcription, ii) binds mainly to enhancer regions, iii) reconfigures the epigenetic landscape through bidirectional alteration of H3K27ac, H3K4me3, and chromatin accessibility, and iv) operates synergistically with NEUROD1. Interestingly, we could not detect a clear hierarchy of FOXG1 and NEUROD1, but instead, provide the evidence that they act in a highly cooperative manner to control neuronal maturation. Genes affected by the chromatin alterations impact synaptogenesis and axonogenesis. Inhibition of histone deacetylases partially rescues transcriptional alterations upon FOXG1 reduction. This integrated multiomics view of changes upon FOXG1 reduction reveals an unprecedented multimodality of FOXG1 functions converging on neuronal maturation. It fuels therapeutic options based on epigenetic drugs to alleviate, at least in part, neuronal dysfunction.
- 4 January 2023
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 120 (2)
Open AccessMultimodal epigenetic changes and altered NEUROD1 chromatin binding in the mouse hippocampus underlie FOXG1 syndrome
Forkhead box G1 (FOXG1) has important functions in neuronal differentiation and balances excitatory/inhibitory network activity. Thus far, molecular processes underlying FOXG1 function are largely unexplored. Here, we present a multiomics data set exploring how FOXG1 impacts neuronal maturation at the chromatin level in the mouse hippocampus. At a genome-wide level, FOXG1 i) both represses and activates transcription, ii) binds mainly to enhancer regions, iii) reconfigures the epigenetic landscape through bidirectional alteration of H3K27ac, H3K4me3, and chromatin accessibility, and iv) operates synergistically with NEUROD1. Interestingly, we could not detect a clear hierarchy of FOXG1 and NEUROD1, but instead, provide the evidence that they act in a highly cooperative manner to control neuronal maturation. Genes affected by the chromatin alterations impact synaptogenesis and axonogenesis. Inhibition of histone deacetylases partially rescues transcriptional alterations upon FOXG1 reduction. This integrated multiomics view of changes upon FOXG1 reduction reveals an unprecedented multimodality of FOXG1 functions converging on neuronal maturation. It fuels therapeutic options based on epigenetic drugs to alleviate, at least in part, neuronal dysfunction.